These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33800561)

  • 21. [Effect of
    Shi Y; Abidan A; Li D; Zibigu R; Wang M; Zheng X; Kang X; Wang H; Li J; Zhang C
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2023 Sep; 35(4):366-373. PubMed ID: 37926471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy.
    Lambert M; Leijonhufvud C; Segerberg F; Melenhorst JJ; Carlsten M
    Methods Mol Biol; 2020; 2121():213-239. PubMed ID: 32147798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout.
    Zhen S; Lu J; Chen W; Zhao L; Li X
    Hum Gene Ther; 2018 Dec; 29(12):1352-1363. PubMed ID: 30457360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies.
    Hasan MF; Campbell AR; Croom-Perez TJ; Oyer JL; Dieffenthaller TA; Robles-Carrillo LD; Cash CA; Eloriaga JE; Kumar S; Andersen BW; Naeimi Kararoudi M; Tullius BP; Lee DA; Copik AJ
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38081778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirtuin 2 up-regulation suppresses the anti-tumour activity of exhausted natural killer cells in mesenteric lymph nodes in murine colorectal carcinoma.
    Jiang B; Ke C; Zhou H; Xia T; Xie X; Xu H
    Scand J Immunol; 2023 Nov; 98(5):e13317. PubMed ID: 38441393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.
    Bexte T; Alzubi J; Reindl LM; Wendel P; Schubert R; Salzmann-Manrique E; von Metzler I; Cathomen T; Ullrich E
    Oncoimmunology; 2022; 11(1):2081415. PubMed ID: 35694192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
    Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
    Front Immunol; 2021; 12():668391. PubMed ID: 34539622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
    Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
    Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrasound microbubble-mediated CRISPR/Cas9 knockout of C-erbB-2 in HEC-1A cells.
    Cai J; Huang S; Yi Y; Bao S
    J Int Med Res; 2019 May; 47(5):2199-2206. PubMed ID: 30983484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.
    Huang BY; Zhan YP; Zong WJ; Yu CJ; Li JF; Qu YM; Han S
    PLoS One; 2015; 10(8):e0134715. PubMed ID: 26266810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer.
    Zhen S; Hua L; Liu YH; Sun XM; Jiang MM; Chen W; Zhao L; Li X
    Oncotarget; 2017 Feb; 8(6):9634-9646. PubMed ID: 28038452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.
    Marx S; Wilken F; Wagner I; Marx M; Troschke-Meurer S; Zumpe M; Bien-Moeller S; Weidemeier M; Baldauf J; Fleck SK; Rauch BH; Schroeder HWS; Lode H; Siebert N
    J Neurooncol; 2020 May; 147(3):577-585. PubMed ID: 32246395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR/Cas9-mediated gene knockout is insensitive to target copy number but is dependent on guide RNA potency and Cas9/sgRNA threshold expression level.
    Yuen G; Khan FJ; Gao S; Stommel JM; Batchelor E; Wu X; Luo J
    Nucleic Acids Res; 2017 Nov; 45(20):12039-12053. PubMed ID: 29036671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins.
    Naeimi Kararoudi M; Dolatshad H; Trikha P; Hussain SA; Elmas E; Foltz JA; Moseman JE; Thakkar A; Nakkula RJ; Lamb M; Chakravarti N; McLaughlin KJ; Lee DA
    J Vis Exp; 2018 Jun; (136):. PubMed ID: 29985369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1α,25(OH)
    Li P; Zhu X; Cao G; Wu R; Li K; Yuan W; Chen B; Sun G; Xia X; Zhang H; Wang X; Yin Z; Lu L; Gao Y
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35318258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.
    Zhang X; Kim WJ; Rao AV; Jaman E; Deibert CP; Sandlesh P; Krueger K; Allen JC; Amankulor NM
    Neurosurg Focus; 2022 Feb; 52(2):E3. PubMed ID: 35104792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions.
    Haspels HN; Rahman MA; Joseph JV; Gras Navarro A; Chekenya M
    Front Immunol; 2018; 9():1345. PubMed ID: 29967607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells.
    Kamali E; Rahbarizadeh F; Hojati Z; Frödin M
    BMC Biotechnol; 2021 Jan; 21(1):9. PubMed ID: 33514392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SRSF3-Regulated RNA Alternative Splicing Promotes Glioblastoma Tumorigenicity by Affecting Multiple Cellular Processes.
    Song X; Wan X; Huang T; Zeng C; Sastry N; Wu B; James CD; Horbinski C; Nakano I; Zhang W; Hu B; Cheng SY
    Cancer Res; 2019 Oct; 79(20):5288-5301. PubMed ID: 31462429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.